Cancer Early Detection
Cancer is a major global health challenge and a leading cause of death worldwide. According to the latest data from the World Health Organization (WHO), there are approximately 20 million new cancer cases and 9.7 million cancer deaths each year. The cancer burden is projected to increase by around 77% by 2050¹.
Early detection and prevention are crucial, as the five-year survival rate for early-stage cancer is 89%, compared to only 20% for advanced-stage cancer. Notably, 59% of cancer deaths result from cancers that are not commonly screened for. Therefore, it is essential to detect cancer at an early stage using non-invasive, highly sensitive tests.
¹American Cancer Society. Global Cancer Facts & Figures 5th Edition. Atlanta: American Cancer Society; 2024.
Multi-Cancer Early Detection (MCED)
Detect cancer signals across different types of tumors
- Minimally invasive blood test capable of detecting early stage cancer signals before symptoms arise and predicting the tumor’s tissue of origin (TOO).
- Employs low-depth whole genome sequencing (WGS) to pinpoint various multidimensional features, including genomic, fragmentomic, and inferred epigenomic features carried by circulating free DNA (cfDNA).
- Highly sensitive tumor early detection technology, Mercury™.
84%
Sensitivity
98%
Specificity
92%
Tracing Accuracy
WHO IS IT FOR
Recommended for individuals aged 45 and older with an average risk of cancer.
SAMPLE TYPE
Peripheral blood
UNDERGO EXTENSIVE VALIDATION STEPS
Total Journal Impact Factor (IF) of 120+ for published CanScan® series-related clinical studies
Case-Control
Study
25,000+ Participants
Prospective & Multi-Center study
Phase I: CanScan® & CanScan® Plus
Feature discovery, model development, and validation in diagnosed individuals, detect 21+ AJCC* cancer type
Phase II: CanScan® Pro
Expanding detectable AJCC* cancer types to 50+ (Ongoing)
Asymptomatic Cohort Study
15,000+ Participants
Prospective Jinling Cohort study
Model validation in asymptomatic individuals aged 45-75 with longitudinal follow up (Ongoing)
*American Joint Committee on Cancer
Limit of use: The CanScan test is not designed to diagnose cancer or replace clinically validated diagnostic procedures. It is not recommended for individuals who are pregnant, have been diagnosed with cancer within the past three years, or are currently receiving active cancer treatment. Rx only
This test does not detect all types of cancer, and in some cases, cancer-related signals may not be detectable in the bloodstream. CanScan analyzes cell-free DNA (cfDNA) patterns in blood to provide insights, but it cannot confirm the presence of current cancer, predict future cancer development, or assess the risk of hereditary or transmissible cancers. It is also not intended for use in cancer monitoring or treatment evaluation.
Furthermore, the test does not evaluate the genetic risk or predisposition to cancer.
For a full understanding of the test’s limitations, please consult your physician and contact Geneseeq’s customer service team.
LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.
Learn more about our products and services or contact us today to discuss how we can partner together.
